Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.

Najima, Yuho

Najima, Yuho.

Affiliation

Najima Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-8-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan. yuhonajima@gmail.com.

Int J Hematol ; 118(2): 169-182, 2023 Aug.

Article in En | MEDLINE | ID: mdl-37036626

Subject(s)

Hematopoietic Stem Cell Transplantation; Leukemia, Myeloid, Acute; Humans; Azacitidine/therapeutic use; fms-Like Tyrosine Kinase 3/genetics; Neoplasm Recurrence, Local/etiology; Transplantation, Homologous/adverse effects; Hematopoietic Stem Cell Transplantation/adverse effects; Chronic Disease; Recurrence

Key words

Allogeneic hematopoietic stem cell transplantation; Azacitidine; FMS-like tyrosine kinase 3; Minimal or measurable residual disease; Post-transplant maintenance treatment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation Type of study: Etiology_studies Limits: Humans Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: Japan Country of publication: Japan

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google